PeptiDream Inc.

4587

JP3836750004

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 11:30:00 28/06/2024 am IST			5-day change	1st Jan Change
2,491 ^JPY	+0.44%		+10.29%	+67.57%

14/06	PeptiDream and Novartis Agreement Becomes Effective with 28.3 Billion Yen Upfront Payment	MT
04/06	National Cancer Center and PeptiDream Announces the First Dosing of Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma	CI

PeptiDream Inc. Provides Consolidated Revenue Guidance for the Fiscal Year Ending December 31, 2022

May 12, 2022 at 12:00 pm IST

PeptiDream Inc. provided consolidated revenue guidance for the fiscal year ending December 31, 2022. For the year, the company expects revenue of JPY 24,500 million.

Latest news about PeptiDream Inc.

PeptiDream and Novartis Agreement Becomes Effective with 28.3 Billion Yen Upfront Payment	14/06	MT
National Cancer Center and PeptiDream Announces the First Dosing of Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma	04/06	CI
Peptidream Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024	14/05	CI
Jefferies Adjusts PeptiDream’s Price Target to 1,900 Yen From 1,400 Yen, Keeps at Hold	07/05	MT
Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis	30/04	CI
PeptiDream Inc. Announces Expansion of Peptide Discovery Collaboration with Novartis Pharma AG	30/04	CI
Certain Preferred Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	13/03	CI
Certain Stock Options of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	13/03	CI
Certain Common Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	13/03	CI
PeptiDream to Partake in Bristol Myers' Tender Offer for All RayzeBio Shares	15/02	MT
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024	14/02	CI
PeptiDream Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/02	CI
Jefferies Adjusts PeptiDream's Price Target to 1,400 Yen From 1,300 Yen, Keeps at Hold	24/01	MT
Linqmed Inc. announced that it has received ¥680 million in funding from a group of investors	22/12	CI
PeptiDream Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	09/11	CI
Jefferies Downgrades PeptiDream to Hold From Buy, Adjusts Price Target to 1,300 Yen From 1,600 Yen	27/23/27	MT
PeptiDream and Bristol-Myers Squibb to Explore Alternatives as PDL1 Program Faces Setback	27/23/27	MT
Peptidream Announces Update on PDL1 Program Partnered with Bristol-Myers Squibb Company	26/23/26	CI
Jefferies Upgrades PeptiDream to Buy From Hold, Adjusts Price Target to 1,600 Yen From 1,900 Yen	18/23/18	MT
PeptiDream Inc. Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide- Radioisotope Drug Conjugates	20/23/20	CI
RayzeBio, Inc. has completed an IPO in the amount of $310.9968 million.	14/23/14	CI
PeptiDream Unit Pays 4 Billion Yen Contingent Consideration for AMYViD Indication Change; Shares Down 3%	11/23/11	MT
PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	09/23/09	CI
PeptiDream Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	09/23/09	CI
Astellas Pharma Inc. and PeptiDream Inc. Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders	25/23/25	CI

PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for PeptiDream Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,491 JPY

Average target price

2,883 JPY

Spread / Average Target

+15.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PEPTIDREAM INC.	+67.57%	200.03Cr
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	12TCr
REGENERON PHARMACEUTICALS, INC.	+19.67%	11TCr
ARGENX SE	+18.95%	2.65TCr
BIONTECH SE	-23.86%	1.94TCr
GENMAB A/S	-19.03%	1.62TCr
BEIGENE, LTD.	-20.90%	1.54TCr
WUXI APPTEC CO., LTD.	-46.14%	1.52TCr
SAREPTA THERAPEUTICS, INC.	+63.85%	1.49TCr
NEUROCRINE BIOSCIENCES, INC.	+4.49%	1.35TCr

Bio Therapeutic Drugs

PeptiDream Inc.

Equities

4587

JP3836750004

Biotechnology & Medical Research

PeptiDream Inc. Provides Consolidated Revenue Guidance for the Fiscal Year Ending December 31, 2022

Latest news about PeptiDream Inc.

Chart PeptiDream Inc.

Company Profile

Income Statement Evolution

Ratings for PeptiDream Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs